Related Experiment Videos
Antitumor lectin-trypsin inhibitor conjugate.
Journal of the National Cancer Institute
|May 1, 1985
Summary
Conjugating Concanavalin A with Acacia confusa trypsin inhibitor created a novel compound (Con A-ACTI) that effectively targeted tumor cells and significantly improved survival in mice with sarcoma 180 tumors.
Area of Science:
- Biochemistry
- Immunology
- Pharmacology
Background:
- Acacia confusa trypsin inhibitor (ACTI) possesses therapeutic potential.
- Concanavalin A (Con A) is a lectin with known biological activities.
- Targeting specific cells, like tumor cells, remains a challenge in drug delivery.
Purpose of the Study:
- To synthesize and characterize a novel conjugate of Con A and ACTI.
- To evaluate the biological activity and tumor-targeting capabilities of the Con A-ACTI conjugate.
- To assess the in vivo efficacy of the conjugate in a sarcoma 180 tumor model.
Main Methods:
- Covalent linkage of Con A and ACTI using N-succinimidyl-3-(2-pyridyldithio)propionate.
- Assay of trypsin inhibitory activity and hemagglutinating activity.
- Evaluation of resistance to tryptic digestion.
- In vitro cell uptake studies with sarcoma 180 cells.
- In vivo efficacy study in mice bearing sarcoma 180 tumors.
Main Results:
- The Con A-ACTI conjugate retained significant trypsin inhibitory activity (42%) and exhibited enhanced hemagglutinating activity.
- The conjugate demonstrated increased resistance to tryptic digestion compared to a mixture of free components.
- Con A-ACTI specifically entered sarcoma 180 tumor cells, unlike free ACTI.
- A single dose of Con A-ACTI significantly increased survival in tumor-bearing mice.
Conclusions:
- Covalent conjugation of Con A and ACTI yields a stable and active conjugate.
- The Con A-ACTI conjugate exhibits enhanced tumor cell targeting and therapeutic efficacy.
- This novel conjugate represents a promising strategy for sarcoma 180 cancer therapy.